Skip to main content
. Author manuscript; available in PMC: 2016 Jan 31.
Published in final edited form as: Lab Invest. 2015 Jun 1;95(8):951–961. doi: 10.1038/labinvest.2015.62

Figure 4. Decreased oncogenic signaling and aggressiveness of DDLPS cells with Met inhibition in vitro.

Figure 4

(A) Western blot analysis monitored decreasing Met, AKT, and Erk1/2 activity levels in Lipo246 cells with increasing concentrations of EMD1214063 (4 h; 10%-FBS containing media). (B) Left Panel; Lipo246 cells. Right Panel; Lipo224 cells: Serum-starved cells were pretreated with increasing concentrations of EMD1214063 followed by rhHGF stimulation for 20 min. Western blot analyses revealed that Met, AKT, and ERK1/2 signaling decreased in a dose-dependent manner. (C) Left Panel: Lipo246; Right panel: Lipo224. MTS assays measured proliferation rates as a consequence of increasing EMD1214063 treatment (n=3 experiments ± SEM; t-test: *=P<0.05, **=P<0.005, ***=P<0.0001; samples were analyzed at least in duplicate per experiment). (D) Serum starved Lipo246 (Left Panel) and Lipo224 (Right Panel) were simultaneously treated with increasing concentrations of EMD1214063 and rhHGF (50 ng/mL) for 96 h. MTS assays revealed that proliferation rates decreased with increasing concentrations of EMD1214063 (n=3 experiments ± SEM; t-test: *=P<0.05, **=P<0.005, ***=P<0.0001; samples were analyzed at least in duplicate per experiment). (E) Left Panel: Lipo246 cells were either treated with DMSO, 100 nM, or 1 μM EMD1214063 for 24 h, and migration and invasion results recorded (3 images per well; at least 2 replicates per experiment; n=3 experiments ± SEM; t-test: *=P<0.05). Right Panel: Lipo224 cells were also either treated with DMSO, 100 nM, or 1 μM EMD1214063 for 24 h (3 images per well; at least 2 replicates per experiment; n=3 experiments ± SEM; t-test: *=P<0.05, **=P<0.005).